Compare Gilead Sciences, Inc. (GILD) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KeyCorp — how do they compare? Gilead Sciences, Inc. trades at $148.6 (market cap $182.40B), while KeyCorp trades at $19.97 (market cap $21.45B). The key difference: Gilead Sciences, Inc. is far larger — about 8.5× KeyCorp's market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and KeyCorp for 66 Days on average.
| GILD | KEY | |
|---|---|---|
Market Cap | $182.40B | $21.45B |
Volume | 4,469,821 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $155.80 | $23.99 |
52-Week Low | $116.74 | $16.78 |
Typical Hold Time | 111 Days | 66 Days |
Enterprise Value | $205.46B | $34.63B |
Dividend Yield | 2.23% | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
KeyCorp (KEY) trades at $19.83, down 1.54% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent management appointments and a 2026 revenue outlook raise to 8% growth signal operational momentum. However, technical indicators show oversold conditions with RSI at 26.31 and bearish moving average signals.
KEY presents a value opportunity with attractive valuation metrics and consistent earnings performance. The 26% upside to consensus price target of $25.00 and 60.79% analyst buy rating support bullish sentiment. Risks include frozen dividend payments since 2023 and sensitivity to interest rate changes. The bank's aggressive share buyback program and improving net interest income provide catalysts for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
